A Phase-I/II Randomized Trial of Maintenance Vaccination Combined With Oral Metronomic Cyclophosphamide With or Without Adoptive Transfer of Vaccine-Primed CD3/CD28-CoStimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Dendritic Cell Vaccine.

Trial Profile

A Phase-I/II Randomized Trial of Maintenance Vaccination Combined With Oral Metronomic Cyclophosphamide With or Without Adoptive Transfer of Vaccine-Primed CD3/CD28-CoStimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Dendritic Cell Vaccine.

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary) ; Cyclophosphamide
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 12 Aug 2009 Planned end date changed from 1 Mar 2010 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 31 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top